David H. Adams
Research Subjects
David H. Adams has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Hong Liu-Seifert
Eli Lilly and Company Indianapolis Indiana USA
2 shared publications John P. Houston
Lilly Research Laboratories, Indianapolis, Indiana, USA
2 shared publicationsAlan Breier
Lilly Research Laboratories, Indianapolis, Indiana, USA
1 shared publicationAnnCatherine M. Downing
Lilly Research Laboratories, Indianapolis, Indiana, USA
1 shared publicationBruce J. Kinon
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN
1 shared publication- Bruce J. Kinon
Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
1 shared publication
Latest Publications
- 4 March 2008
- Published by Wiley in Human Psychopharmacology: Clinical and Experimental
- Vol. 23 (4) , 267-274
Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately caucasian patients with chronic schizophrenia or schizoaffective disorder
Objective: To test association of dopamine receptor D3 (DRD‐3) gene polymorphisms with olanzapine response in genetic samples from a registration phase clinical trial.Methods: Eighty‐eight acutely ill patients with schizophrenia or schizoaffective disorder were genotyped for ser‐9‐gly (rs6280) and 23 other polymorphisms within the DRD‐3 gene. Allelic association of clinical response (mean baseline‐ to‐endpoint reduction in Positive and Negative Syndrome Scale [PANSS] total and subscores) over 6 weeks of olanzapine treatment was assessed using repeated measures analysis of variance.Results: Ser‐9‐gly genotypes were associated with differences in PANSS total score improvement from baseline to 6 weeks (p = 0.021). This association was most notable for improvement in positive symptoms (p = 0.0001), with patients with gly/gly genotype significantly more responsive. More patients with the gly/gly genotype had greater positive symptom remission (endpoint rating of minimal or none on all PANSS positive items, 39.1%) compared with patients with gly/ser and ser/ser genotypes (13.8%;p = 0.033). DRD‐3 polymorphisms in disequilibrium with ser‐9‐gly were also significantly associated with greater positive symptom improvement (p = 0.0009–0.021), and one not in complete linkage disequilibrium, with lesser improvement (p = 0.027).Conclusions: Gly/gly DRD‐3 genotype predicted statistically and clinically significantly better acute positive symptom reduction compared with other ser‐9‐gly genotypes in patients treated with olanzapine. Copyright © 2008 John Wiley & Sons, Ltd.
- 4 March 2008
- Published by Wiley in Human Psychopharmacology: Clinical and Experimental
- Vol. 23 (4) , 267-274
Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately caucasian patients with chronic schizophrenia or schizoaffective disorder
Objective: To test association of dopamine receptor D3 (DRD‐3) gene polymorphisms with olanzapine response in genetic samples from a registration phase clinical trial.Methods: Eighty‐eight acutely ill patients with schizophrenia or schizoaffective disorder were genotyped for ser‐9‐gly (rs6280) and 23 other polymorphisms within the DRD‐3 gene. Allelic association of clinical response (mean baseline‐ to‐endpoint reduction in Positive and Negative Syndrome Scale [PANSS] total and subscores) over 6 weeks of olanzapine treatment was assessed using repeated measures analysis of variance.Results: Ser‐9‐gly genotypes were associated with differences in PANSS total score improvement from baseline to 6 weeks (p = 0.021). This association was most notable for improvement in positive symptoms (p = 0.0001), with patients with gly/gly genotype significantly more responsive. More patients with the gly/gly genotype had greater positive symptom remission (endpoint rating of minimal or none on all PANSS positive items, 39.1%) compared with patients with gly/ser and ser/ser genotypes (13.8%;p = 0.033). DRD‐3 polymorphisms in disequilibrium with ser‐9‐gly were also significantly associated with greater positive symptom improvement (p = 0.0009–0.021), and one not in complete linkage disequilibrium, with lesser improvement (p = 0.027).Conclusions: Gly/gly DRD‐3 genotype predicted statistically and clinically significantly better acute positive symptom reduction compared with other ser‐9‐gly genotypes in patients treated with olanzapine. Copyright © 2008 John Wiley & Sons, Ltd.
- Open Access
- 7 January 2008
- Published by Springer Nature in BMC Psychiatry
- Vol. 8 (1) , 3
Evaluating dose response from flexible dose clinical trials
The true dose effect in flexible-dose clinical trials may be obscured and even reversed because dose and outcome are related. To evaluate dose effect in response on primary efficacy scales from 2 randomized, double-blind, flexible-dose trials of patients with bipolar mania who received olanzapine (N = 234, 5–20 mg/day), or patients with schizophrenia who received olanzapine (N = 172, 10–20 mg/day), we used marginal structural models, inverse probability of treatment weighting (MSM, IPTW) methodology. Dose profiles for mean changes from baseline were evaluated using weighted MSM with a repeated measures model. To adjust for selection bias due to non-random dose assignment and dropouts, patient-specific time-dependent weights were determined as products of (i) stable weights based on inverse probability of receiving the sequence of dose assignments that was actually received by a patient up to given time multiplied by (ii) stable weights based on inverse probability of patient remaining on treatment by that time. Results were compared with those by unweighted analyses. While the observed difference in efficacy scores for dose groups for the unweighted analysis strongly favored lower doses, the weighted analyses showed no strong dose effects and, in some cases, reversed the apparent "negative dose effect." While naïve comparison of groups by last or modal dose in a flexible-dose trial may result in severely biased efficacy analyses, the MSM with IPTW estimators approach may be a valuable method of removing these biases and evaluating potential dose effect, which may prove useful for planning confirmatory trials.
- 7 January 2008
- Published by Springer Nature in BMC Psychiatry
- Vol. 8 (1) , 3
Open AccessEvaluating dose response from flexible dose clinical trials
The true dose effect in flexible-dose clinical trials may be obscured and even reversed because dose and outcome are related. To evaluate dose effect in response on primary efficacy scales from 2 randomized, double-blind, flexible-dose trials of patients with bipolar mania who received olanzapine (N = 234, 5–20 mg/day), or patients with schizophrenia who received olanzapine (N = 172, 10–20 mg/day), we used marginal structural models, inverse probability of treatment weighting (MSM, IPTW) methodology. Dose profiles for mean changes from baseline were evaluated using weighted MSM with a repeated measures model. To adjust for selection bias due to non-random dose assignment and dropouts, patient-specific time-dependent weights were determined as products of (i) stable weights based on inverse probability of receiving the sequence of dose assignments that was actually received by a patient up to given time multiplied by (ii) stable weights based on inverse probability of patient remaining on treatment by that time. Results were compared with those by unweighted analyses. While the observed difference in efficacy scores for dose groups for the unweighted analysis strongly favored lower doses, the weighted analyses showed no strong dose effects and, in some cases, reversed the apparent "negative dose effect." While naïve comparison of groups by last or modal dose in a flexible-dose trial may result in severely biased efficacy analyses, the MSM with IPTW estimators approach may be a valuable method of removing these biases and evaluating potential dose effect, which may prove useful for planning confirmatory trials.
- 1 August 2007
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 27 (4) , 392-394
Association of Acute Symptoms and Compliance Attitude in Noncompliant Patients With Schizophrenia
- 1 August 2007
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 27 (4) , 392-394
Association of Acute Symptoms and Compliance Attitude in Noncompliant Patients With Schizophrenia
- Open Access
- 23 December 2005
- Published by Springer Nature in BMC Medicine
- Vol. 3 (1) , 21
Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs
Background: Stopping antipsychotic treatment can interrupt improvement and exacerbate the illness. The reasons for discontinuing treatment during controlled clinical trials were analyzed to explore this phenomenon. Methods: A post-hoc, pooled analysis was made of 4 randomized, double-blind clinical trials, 24–28 weeks in duration, involving 1627 patients with schizophrenia or a related disorder. Analyses combined all the atypical antipsychotic treatment groups in the studies. Results: The majority of patients (53%) stopped their treatment at an early stage. Poor psychiatric response along with worsening symptoms was the most frequently given reason for discontinuing the course (36%), which was substantially more common than discontinuation due to poor tolerability of the medication (12%). This phenomenon was corroborated by less improvement in patients who discontinued treatment compared with those who completed, based on the PANSS total scores. Discontinuation due to poor response was, apparently, more predominantly linked to patient perception than to physicians' conclusions alone (80% vs. 20%). Discontinuation due to patient perception of poor response appeared to occur particularly early in the course of treatment. Patients who discontinued due to poor toleration of the medication responded in a more comparable manner with completers. Conclusion: Discontinuing treatment may lead to exacerbation of symptoms, undermining therapeutic progress. In these studies, poor response to treatment and worsening of underlying psychiatric symptoms, and to a lesser extent, intolerability to medication were the primary contributors to treatment being discontinued. Our findings suggest that adherence may be enhanced by effective symptom control, as objectively measured and as subjectively perceived. Such strategies may improve patients' willingness to undertake long-term therapy and increase the likelihood of a better prognosis.
- 23 December 2005
- Published by Springer Nature in BMC Medicine
- Vol. 3 (1) , 21
Open AccessDiscontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs
Background: Stopping antipsychotic treatment can interrupt improvement and exacerbate the illness. The reasons for discontinuing treatment during controlled clinical trials were analyzed to explore this phenomenon. Methods: A post-hoc, pooled analysis was made of 4 randomized, double-blind clinical trials, 24–28 weeks in duration, involving 1627 patients with schizophrenia or a related disorder. Analyses combined all the atypical antipsychotic treatment groups in the studies. Results: The majority of patients (53%) stopped their treatment at an early stage. Poor psychiatric response along with worsening symptoms was the most frequently given reason for discontinuing the course (36%), which was substantially more common than discontinuation due to poor tolerability of the medication (12%). This phenomenon was corroborated by less improvement in patients who discontinued treatment compared with those who completed, based on the PANSS total scores. Discontinuation due to poor response was, apparently, more predominantly linked to patient perception than to physicians' conclusions alone (80% vs. 20%). Discontinuation due to patient perception of poor response appeared to occur particularly early in the course of treatment. Patients who discontinued due to poor toleration of the medication responded in a more comparable manner with completers. Conclusion: Discontinuing treatment may lead to exacerbation of symptoms, undermining therapeutic progress. In these studies, poor response to treatment and worsening of underlying psychiatric symptoms, and to a lesser extent, intolerability to medication were the primary contributors to treatment being discontinued. Our findings suggest that adherence may be enhanced by effective symptom control, as objectively measured and as subjectively perceived. Such strategies may improve patients' willingness to undertake long-term therapy and increase the likelihood of a better prognosis.